Nội dung được dịch bởi AI, chỉ mang tính chất tham khảo
Tích tụ sắt cơ tim trong bệnh thalassemia phụ thuộc truyền máu và bệnh hồng cầu hình liềm
Tóm tắt
Từ khóa
Tài liệu tham khảo
Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet. 1989;2: 27-30.
Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000;355: 2051-2052.
Ehlers KH, Giardina PJ, Lesser ML, Engle MA, Hiltgartner MW. Prolonged survival in patients with beta-thalassemia major treated with deferoxamine. J Pediatr. 1991;118(part 1): 540-545.
Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci. 1998;850: 227-231.
Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22: 2171-2179.
Mavrogeni SI, Gotsis ED, Markussis V, et al. T2 relaxation time study of iron overload in β-thalassemia. MAGMA. 1998;6: 7-12.
Papanikolaou N, Ghiatas A, Kattamis A, Ladis C, Kritikos N, Kattamis C. Non-invasive myocardial iron assessment in thalassaemic patients: T2 relaxometry and magnetization transfer ratio measurements. Acta Radiol. 2000;41: 348-351.
Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet. 2002;360: 516-520.
Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89: 739-761.
Covitz W, Espeland M, Gallagher D, Hellenbrand W, Leff S, TalnerN. The heart in sickle cell anemia: the Cooperative Study of Sickle Cell Disease (CSSCD). Chest. 1995;108: 1214-1219.
Batra AS, Acherman RJ, Wong WY, et al. Cardiac abnormalities in children with sickle cell anemia. Am J Hematol. 2002;70: 306-312.
Lorenz CH. The range of normal values of cardiovascular structures in infants, children, and adolescents measured by magnetic resonance imaging. Pediatr Cardiol. 2000;21: 37-46.
Lorenz CH, Walker ES, Morgan VL, Klein SS, Graham TP Jr. Normal human right and left ventricular mass, systolic function, and gender differences by cine magnetic resonance imaging. J Cardiovasc Magn Reson. 1999;1: 7-21.
Salton CJ, Chuang ML, O'Donnell CJ, et al. Gender differences and normal left ventricular anatomy in an adult population free of hypertension: a cardiovascular magnetic resonance study of the Framingham Heart Study Offspring cohort. J Am Coll Cardiol. 2002;39: 1055-1060.
Nienhuis AW, Griffith P, Strawczynski H, et al. Evaluation of cardiac function in patients with thalassemia major. Ann N Y Acad Sci. 1980;344: 384-396.
Shah FT, Westwood MA, Evans PJ, Porter JB. Discordance in MRI Assessment in Iron Distribution and Plasma NTBI between Transfusionally Iron Loaded Adults with Sickle Cell and Thalassemia [abstract]. Blood. 2002;100: 668a.
Vichinsky EP. Current issues with blood transfusions in sickle cell disease. Semin Hematol. 2001;38(suppl 1): 14-22.
Buja LM, Roberts WC. Iron in the heart: etiology and clinical significance. Am J Med. 1971;51: 209-221.
Vigorita VJ, Hutchins GM. Cardiac conduction system in hemochromatosis: clinical and pathologic features of six patients. Am J Cardiol. 1979; 44: 418-423.
Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331: 567-573.
Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331: 574-578.
Jensen PD, Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood. 2003;101: 4632-4639.